Manufacturer of Controlled Substances; Notice of Application; Euticals, Inc., 53480 [2013-21136]

Download as PDF 53480 Federal Register / Vol. 78, No. 168 / Thursday, August 29, 2013 / Notices containing wastewater. The Consent Decree includes a supplemental environmental project requiring Big West Oil to install, at a cost of approximately $253,000, a laser detection system around the perimeter of the Hydrofluoric Acid (‘‘HF’’) Alkylation Unit that will provide earlier detection of much lower levels of HF. The publication of this notice opens a period for public comment on the Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States and State of Utah v. Big West Oil, LLC, D.J. Ref. No. 90–5–2–1–07689. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail: To submit comments: Send them to: By e-mail pubcommentees.enrd@usdoj.gov. Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, D.C. 20044– 7611. By mail ..... During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http:// www.justice.gov/enrd/ Consent_Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $35.50 (25 cents per page reproduction cost) payable to the United States Treasury. Maureen Katz, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. Drug Enforcement Administration sroberts on DSK5SPTVN1PROD with NOTICES Gamma Hydroxybutyric Acid (2010). Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Phenylacetone (8501) .................. Methadone intermediate (9254) ... Tapentadol (9780) ........................ I II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers. In reference to Amphetamine (1100), the company plans to acquire the listed controlled substance in bulk from a domestic source in order to manufacture other controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 28, 2013. Dated: August 22, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–21136 Filed 8–28–13; 8:45 am] BILLING CODE 4410–09–P The Legal Services Corporation’s Institutional Advancement Committee will meet telephonically on September 3, 2013. The meeting will commence at 4:00 p.m., EDT, and will continue until the conclusion of the Committee’s agenda. LOCATION: John N. Erlenborn Conference Room, Legal Services Corporation Headquarters, 3333 K Street NW., Washington DC 20007. STATUS OF MEETING: Upon a vote of the Board of Directors, the meeting may be closed to the public to discuss prospective funders for LSC’s 40th DATE AND TIME: DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Application; Euticals, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 28, 2013, Euticals, Inc., 2460 W. Bennett Street, Springfield, Missouri 65807–1229, made Jkt 229001 Schedule Sunshine Act Meeting BILLING CODE 4410–15–P 18:34 Aug 28, 2013 Drug LEGAL SERVICES CORPORATION [FR Doc. 2013–21079 Filed 8–28–13; 8:45 am] VerDate Mar<15>2010 application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: PO 00000 Frm 00059 Fmt 4703 Sfmt 9990 anniversary celebration and development activities and prospective members for LSC’s 40th anniversary committees. A verbatim transcript will be made of the closed session meeting of the Institutional Advancement Committee. The transcript of any portion of the closed session falling within the relevant provision of the Government in the Sunshine Act, 5 U.S.C. 552b(c)(6) will not be available for public inspection. A copy of the General Counsel’s Certification that, in his opinion, the closing is authorized by law will be available upon request. MATTERS TO BE CONSIDERED: Closed 1. Approval of agenda 2. Discussion of prospective funders for LSC’s 40th anniversary celebration and development activities 3. Discussion of prospective members for LSC’s 40th anniversary committees 4. Consider and act on adjournment of meeting CONTACT PERSON FOR INFORMATION: Katherine Ward, Executive Assistant to the Vice President & General Counsel, at (202) 295–1500. Questions may be sent by electronic mail to FR_NOTICE_ QUESTIONS@lsc.gov. LSC complies with the Americans with Disabilities Act and Section 504 of the 1973 Rehabilitation Act. Upon request, meeting notices and materials will be made available in alternative formats to accommodate individuals with disabilities. Individuals needing other accommodations due to disability in order to attend the meeting in person or telephonically should contact Katherine Ward, at (202) 295–1500 or FR_ NOTICE_QUESTIONS@lsc.gov, at least 2 business days in advance of the meeting. If a request is made without advance notice, LSC will make every effort to accommodate the request but cannot guarantee that all requests can be fulfilled. ACCESSIBILITY: Dated: August 26, 2013. Atitaya C. Rok, Staff Attorney. [FR Doc. 2013–21212 Filed 8–27–13; 11:15 am] BILLING CODE 7050–01–P E:\FR\FM\29AUN1.SGM 29AUN1

Agencies

[Federal Register Volume 78, Number 168 (Thursday, August 29, 2013)]
[Notices]
[Page 53480]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-21136]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Euticals, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 28, 2013, Euticals, 
Inc., 2460 W. Bennett Street, Springfield, Missouri 65807-1229, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)...........  I
Amphetamine (1100).........................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Phenylacetone (8501).......................  II
Methadone intermediate (9254)..............  II
Tapentadol (9780)..........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution and sale to its customers.
    In reference to Amphetamine (1100), the company plans to acquire 
the listed controlled substance in bulk from a domestic source in order 
to manufacture other controlled substances in bulk for distribution to 
its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 28, 2013.

    Dated: August 22, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-21136 Filed 8-28-13; 8:45 am]
BILLING CODE 4410-09-P